Patient-controlled sedation with propofol in ERCP:alfentanyl vs remifentanyl

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2009-012398-36-FI

Enrollment

Registered

2009-05-15

Start date

2009-06-18

Completion date

Unknown

Last updated

2014-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Billiar tract and pancreatic disoderes MedDRA version: 9.1 Level: LLT Classification code 10004676 Term: Biliary tract disease MedDRA version: 9.1 Level: LLT Classification code 10004677 Term: Biliary tract disorder NOS MedDRA version: 9.1 Level: LLT Classification code 10033616 Term: Pancreatic disorder

Interventions

Trade Name: Ultiva Product Name: ULTIVA Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: REMIFENTANIL CAS Number: 132875617 Trade Name: RAPIFEN Product Name: R

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -elective ERCP patients; -age 18-70 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: -allergy to medcines; -dementia,mentally handicapped; -grievous liver or kidneys failure; -significant heart failure or pulmonary disease

Design outcomes

Primary

Measure	Time frame
Main Objective: Main objective of the trial is to compare alfentanyl and remifentanyl in patient-controlled sedation during endoscopic retrograde cholangio-pancreatography.;Secondary Objective: degree of sedation,medcines demand,komplications,recovery time,paine estimation ;Primary end point(s): Pulse,Blood pressure,Oxygen saturation,complications,recovery time	—

Countries

Finland

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026